SCYNEXIS, Inc.

Greetings, and welcome to the Cinexus Third Quarter 2021 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Debbie Etchison, Executive Director of Communications. Thank you. You may begin.

Hello, everyone, and welcome to today's conference call to discuss our third quarter 2021 financial results and corporate update. Before we start, let me remind you that today's call will include forward-looking statements based on current expectations, including statements concerning our financial outlook for the future, leadership expectations for our future financial and operational performance, as well as our business strategy. Because such statements are subject to risks and uncertainties, Actual results may differ materially from those expressed or implied by such forward-looking statements. Please refer to our filings with the Securities and Exchange Commission, including our most recent annual report on Form 10-K and quarterly report on Form 10-Q, included in each case under the caption, Risk Factors, and in other documents subsequently filed or furnished to the Securities and Exchange Commission. All forward-looking statements speak only as of today, November 10th, 2021. Cenexus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they're made. The information on today's call is not intended for promotional purposes and not sufficient for prescribing decisions. Joining us today on the call are Cenexus President and CEO, Dr. Marco Taglietti, Chief Commercial Officer, Christine Coyne, Chief Medical Officer, Dr. David Angulo, and Chief Financial Officer, Eric Francois. Following our prepared remarks, we'll open the call to your questions. Now I will return the call over to Dr. Marco Tagliati.

Thank you, Debbie. Good morning, everyone. Buongiorno a tutti. Thank you for joining us today for our third quarter 2021 Earnings Investor Call, our inaugural earnings call with investors since the FDA approval in June and after the launch of Prexafen. For all of you who have been following us in the last few years, you witness how we have been true to our word, commitments and timelines to turn our vision for Ibrexafunger into reality. Our vision for Ibrexafunger has always been to build a global antifungal franchise for both community and hospital infections. by leveraging the versatility and potency of a Brexaphone jerk and to extract the full value of this unique, systemic antifungal agent for the benefit of patients and for the reward of our shareholders. And with 14 years of exclusivity until 2035, we have the time to build a solid, long-lasting antifungal franchise to create a stream of approvals over the years to continue to expand its use. So, today you will hear about the significant progress we have made so far in achieving our vision for Edressa Fungerba. First, you will hear from Christine, our Chief Commercial Officer, who will provide an overview of the market, our commercial activities, and the promising early trend of the launch of BrexFM for the treatment of vulvovaginal candidiasis. We are very excited about bringing innovation from a new antifungal class to the millions of women suffering from this symptomatic condition who have been underserved for so long. We are so proud to bring to patients the first new antifungal class in more than 20 years. Then you will hear from David, our chief medical officer, about our significant progress in research and development. We are finishing the phase three candle study for the prevention of recurrent BBC, which, assuming positive data, may result in a second approval for a breast upon jerk in the second half of next year. David will also give you an update about our liposomal intravenous formulation. We successfully completed the phase one in healthy volunteers, opening new avenues of development for hospital invasive fungal infections on top of our ongoing hospital programs. And finally, all our commercial and R&D activities are built on a solid financial foundation. Our chief financial officer will give you a brief financial update. Now, I would like to turn the call over to Christine Coyne. Christine?